Skip to main content
SpringerLink
Log in

Pharmacokinetics of adalimumab in Crohn’s disease

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerre T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G (2014) Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 2014(16):12509

    Google Scholar 

  2. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6):1700–1721

    Article  CAS  PubMed  Google Scholar 

  3. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P (2009) Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 137(5):1628–1640

    Article  CAS  PubMed  Google Scholar 

  4. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468. doi:10.1001/jama.2011.406

    Article  CAS  PubMed  Google Scholar 

  5. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921–926

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739–1745. doi:10.1136/ard.2008.092833

    Article  CAS  PubMed  Google Scholar 

  7. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 28(9):1122–1126

    Article  CAS  PubMed  Google Scholar 

  8. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211–1228. doi:10.1007/s00228-009-0718-4

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523–529

    CAS  PubMed  Google Scholar 

  10. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G (2012) Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 73(1):55–65

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H (2008) Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48(6):681–695

    Article  CAS  PubMed  Google Scholar 

  12. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G (2006) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 28(2):169–174

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Measurements of adalimumab serum concentrations were carried out within the CePiBAc platform. CePiBAc was cofinanced by the European Union. Europe is committed to the region Centre with the European Regional Development Fund. This work was partly supported by the French Higher Education and Research ministry under the program ‘Investissements d’avenir’ Grant Agreement: LabEx MAbImprove ANR-10-LABX-53–01. The authors thank Anne-Claire Duveau and Caroline Brochon for technical assistance with adalimumab assays.

Authors’ contribution

D. Ternant participated actively in execution of the study, analyzed and interpreted the data, and wrote the manuscript.

K. Karmiris, G. Van Assche, and S. Vermeire conceived the ideas and experimental design and participated actively in execution of the study.

C. Desvignes participated actively in execution of the study.

N. Azzopardi participated actively in execution of the study and to the analysis of the data.

T. Bejan-Angoulvant participated to the analysis of the data.

G. Paintaud participated to the conception of the ideas and experimental design, and participated actively in execution of the study, to the analysis and interpretation of the data, and to the writing of the manuscript.

Conflict of interest

K. Karmiris reports personal fees from Abbvie and MSD outside the submitted work.

S. Vermeire reports grants and personal fees from UCB Pharma, Abbvie, Merck, and J&J and personal fees from Pfizer, Genentech/Roche, Takeda, Ferring, Celltrion, Mundipharma, Hospira, and Shire during the conduct of the study.

G. van Assche reports reports and Consultancy and/or honoraria from the following: Abbvie, Takeda, MSD, Janssen, and Falk. Research support to University of Leuven was from Abbvie.

G. Paintaud reports grants from Novartis, Roche Pharma, Genzyme, MSD, Servier, and Pfizer outside the submitted work.

D. Ternant, C. Desvignes, N. Azzopardi, and T. Bejan-Angoulvant declare that they have no competing interest.

Author information

Authors and Affiliations

  1. Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France

    David Ternant, Céline Desvignes, Nicolas Azzopardi, Theodora Bejan-Angoulvant & Gilles Paintaud

  2. CHRU de Tours, Laboratoire de Pharmacologie-Toxicologie, 2 boulevard Tonnellé, 37044, Tours Cedex, France

    David Ternant, Céline Desvignes & Gilles Paintaud

  3. Department of Gastroenterology, University Hospital, Leuven, Belgium

    Konstantinos Karmiris, Severine Vermeire & Gert van Assche

  4. CHRU de Tours, Service de Pharmacologie, Tours, France

    Theodora Bejan-Angoulvant

Authors
  1. David Ternant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos Karmiris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Severine Vermeire
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Céline Desvignes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Azzopardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theodora Bejan-Angoulvant
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gert van Assche
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gilles Paintaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Ternant.

Additional information

Konstantinos Karmiris is the Principal investigator.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ternant, D., Karmiris, K., Vermeire, S. et al. Pharmacokinetics of adalimumab in Crohn’s disease. Eur J Clin Pharmacol 71, 1155–1157 (2015). https://doi.org/10.1007/s00228-015-1892-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1892-1

Keywords

Search

Navigation